Compare Stocks: RYM, ZNTL, DERM, and NERV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.61 -1.6%	$6.97	$4.31 ▼ $9.56	$186.53M	1.1	216,514 shs	125,128 shs
NERV Minerva Neurosciences	$3.28 +1.5%	$4.18	$2.08 ▼ $12.46	$156.62M	-0.1	209,961 shs	57,021 shs
RYM RYTHM	$19.35 -3.3%	$21.98	$14.00 ▼ $53.65	$42.17M	9.46	14,882 shs	20,957 shs
ZNTL Zentalis Pharmaceuticals	$2.52 -3.4%	$3.78	$1.21 ▼ $6.95	$180.61M	1.93	1.56 million shs	1.45 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	-1.75%	+6.33%	-11.23%	-5.22%	-7.31%
NERV Minerva Neurosciences	-3.73%	-6.38%	-27.90%	-36.67%	+53.81%
RYM RYTHM	-4.63%	-9.67%	-11.66%	-19.98%	-51.39%
ZNTL Zentalis Pharmaceuticals	-5.78%	-5.09%	-29.65%	-41.48%	+69.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.61 -1.6%	$6.97	$4.31 ▼ $9.56	$186.53M	1.1	216,514 shs	125,128 shs
NERV Minerva Neurosciences	$3.28 +1.5%	$4.18	$2.08 ▼ $12.46	$156.62M	-0.1	209,961 shs	57,021 shs
RYM RYTHM	$19.35 -3.3%	$21.98	$14.00 ▼ $53.65	$42.17M	9.46	14,882 shs	20,957 shs
ZNTL Zentalis Pharmaceuticals	$2.52 -3.4%	$3.78	$1.21 ▼ $6.95	$180.61M	1.93	1.56 million shs	1.45 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	-1.75%	+6.33%	-11.23%	-5.22%	-7.31%
NERV Minerva Neurosciences	-3.73%	-6.38%	-27.90%	-36.67%	+53.81%
RYM RYTHM	-4.63%	-9.67%	-11.66%	-19.98%	-51.39%
ZNTL Zentalis Pharmaceuticals	-5.78%	-5.09%	-29.65%	-41.48%	+69.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.25	Hold	$14.00	111.00% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	218.93% Upside
RYM RYTHM	1.00	Sell	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.40	Hold	$6.75	163.16% Upside

Current Analyst Ratings Breakdown

Latest RYM, ZNTL, DERM, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/6/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$61.86M	3.03	N/A	N/A	$0.96 per share	6.91
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
RYM RYTHM	$17.28M	2.52	N/A	N/A	$6.06 per share	3.30
ZNTL Zentalis Pharmaceuticals	$67.43M	2.73	N/A	N/A	$2.99 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$11.43M	-$0.22	N/A	7.37	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest RYM, ZNTL, DERM, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	0.64	1.59	1.41
NERV Minerva Neurosciences	N/A	20.15	20.14
RYM RYTHM	N/A	0.59	0.56
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
NERV Minerva Neurosciences	34.56%
RYM RYTHM	5.98%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	14.53%
NERV Minerva Neurosciences	1.70%
RYM RYTHM	3.48%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	58	28.22 million	24.12 million	N/A
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable
RYM RYTHM	141	2.18 million	2.10 million	N/A
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

RYM, ZNTL, DERM, and NERV Headlines

Recent News About These Companies

Wells Fargo sets USD 5.00 target for Zentalis Pharmaceuticals stock

October 2 at 7:11 AM | ad-hoc-news.deA

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Picked Up by Analysts at Wells Fargo & Company

October 2 at 1:43 AM | americanbankingnews.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1 at 5:10 PM | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated by Analysts at Wells Fargo & Company

September 30 at 10:05 AM | marketbeat.com

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Newly Acquired by Bank of America Corp DE

September 29 at 3:03 AM | marketbeat.com

Financial Contrast: Harmony Biosciences (NASDAQ:HRMY) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 22, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

September 18, 2026 | ad-hoc-news.deA

William Blair Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 16, 2026 | marketbeat.com

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

September 16, 2026 | streetinsider.com

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

September 10, 2026 | marketbeat.com

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4, 2026 | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM, ZNTL, DERM, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

$6.61 -0.11 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Minerva Neurosciences NASDAQ:NERV

$3.28 +0.05 (+1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$3.27 -0.01 (-0.30%)

As of 04:17 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

RYTHM NASDAQ:RYM

$19.34 -0.66 (-3.28%)

Closing price 03:58 PM Eastern

Extended Trading

$19.34 0.00 (0.00%)

As of 04:27 PM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.52 -0.09 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$2.49 -0.03 (-1.19%)

As of 04:43 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RYM, ZNTL, DERM, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RYM, ZNTL, DERM, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RYM, ZNTL, DERM, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM, ZNTL, DERM, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

Minerva Neurosciences NASDAQ:NERV

RYTHM NASDAQ:RYM

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RYM, ZNTL, DERM, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RYM, ZNTL, DERM, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RYM, ZNTL, DERM, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM, ZNTL, DERM, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

Minerva Neurosciences NASDAQ:NERV

RYTHM NASDAQ:RYM

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools